Results 161 to 169 of about 19,369 (169)

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

New England Journal of Medicine, 2020
Reinhard Dummer, Mario Santinami, Victoria Atkinson   +2 more
exaly  

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Lancet Oncology, The, 2016
Benjamin Besse, Harry J M Groen, Fabrice Barlesi   +2 more
exaly  

Dabrafenib/trametinib/trametinib

Reactions Weekly
openaire   +1 more source

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

New England Journal of Medicine, 2015
Caroline Robert, Piotr Rutkowski, Andrzej Mackiewicz   +2 more
exaly  

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

New England Journal of Medicine, 2019
Caroline Robert, Daniil Stroyakovskiy, Evgeny Levchenko   +2 more
exaly  

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Lancet Oncology, The, 2018
Rodabe N Amaria, Michael T Tetzlaff, Alexandre Reuben   +2 more
exaly  

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Lancet Oncology, The, 2015
Jean Jacques Grob, Reinhard Dummer, Andrzej Mackiewicz   +2 more
exaly  

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

Nature Medicine
Georgina V Long, Andrew J Spillane, Kerwin F Shannon   +2 more
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly